PMGC Holdings (ELAB) Work In Process (2023 - 2026)

PMGC Holdings (ELAB) posted Work In Process of $83849.0 for Q1 2026, down 71.0% sequentially from $289113.0 in Q3 2024.

PMGC Holdings (ELAB) Work In Process (2023 - 2026) Analysis & Trends

PMGC Holdings has reported Work In Process for 3 years, with the latest figure at $83849.0 in Q1 2026.

Quarterly Work In Process changed N/A year-over-year to $83849.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $83849.0 (changed N/A YoY) and the FY2023 annual result came in at $147906.0, changed N/A from the prior year.
Work In Process retreated to $83849.0 in Q1 2026 per ELAB's latest filing, from $289113.0 in the prior quarter.
Over five years, Work In Process peaked at $290080.0 in Q2 2024 and troughed at $83849.0 in Q1 2026.
A 3-year average of $218945.6 and a median of $283780.0 in 2024 frame the typical range for Work In Process.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	PMGC Holdings	3.01 Mn	-15.78 Mn	385,691.00

Download Data